Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

NCT01630083 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
CLDN18.2-positive Adenocarcinoma of Esophagus
CLDN18.2-positive Gastric Adenocarcinoma

Interventions

DRUG: epirubicin
DRUG: oxaliplatin
DRUG: capecitabine
DRUG: zolbetuximab

Sponsor

Astellas Pharma Global Development, Inc.